Most drug candidates in development for cardiometabolic diseases focus on hitting one target and hitting it hard. This approach can throw other parts of the system out of whack, as illustrated by new warnings of diabetes risk added to the labels of statins.

A more balanced approach may be Esperion Therapeutics Inc.'s Phase II lipid modulator, which appears to have a beneficial effect on a host of risk factors including atherogenic lipids and lipoproteins, inflammation, blood pressure and glucose.